• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Hepatocellular carcinoma in patients with no identifiable risk factors.无明确危险因素的肝细胞癌。
HPB (Oxford). 2021 Jan;23(1):118-126. doi: 10.1016/j.hpb.2020.05.005. Epub 2020 Jun 24.
2
Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database.射频消融与手术切除治疗肝细胞癌:来自美国国家癌症数据库的当代治疗趋势和结果。
Eur Radiol. 2019 May;29(5):2679-2689. doi: 10.1007/s00330-018-5902-4. Epub 2018 Dec 17.
3
[A new prognostic score system of hepatocellular carcinoma following hepatectomy].[一种肝切除术后肝细胞癌的新预后评分系统]
Zhonghua Zhong Liu Za Zhi. 2017 Dec 23;39(12):903-909. doi: 10.3760/cma.j.issn.0253-3766.2017.12.005.
4
Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection.根治性切除术后肝细胞癌肝外复发的临床病理特征及危险因素。
World J Surg. 2012 Jan;36(1):136-43. doi: 10.1007/s00268-011-1317-y.
5
Impact of viral hepatitis on outcomes after liver resection for hepatocellular carcinoma: results from a north american center.病毒性肝炎对肝细胞癌肝切除术后结局的影响:来自北美一个中心的结果
Ann Surg Oncol. 2014 Aug;21(8):2708-16. doi: 10.1245/s10434-014-3609-6. Epub 2014 May 8.
6
Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.20年间接受肝切除手术的非酒精性脂肪性肝病相关肝癌患者的时间趋势、临床模式及预后
Aliment Pharmacol Ther. 2017 Nov;46(9):856-863. doi: 10.1111/apt.14261. Epub 2017 Aug 31.
7
Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases.BCLC-B 期肝细胞癌肝切除术的手术和肿瘤学结果:474 例连续病例的回顾性多中心分析。
Updates Surg. 2019 Jun;71(2):285-293. doi: 10.1007/s13304-019-00649-w. Epub 2019 Apr 2.
8
Recurrence of Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma After Hepatectomy.巴塞罗那临床肝癌分期A期肝细胞癌肝切除术后复发
Am J Med Sci. 2017 Sep;354(3):262-267. doi: 10.1016/j.amjms.2017.05.014. Epub 2017 May 25.
9
Risk factors for early recurrence of HBV-related hepatocellular carcinoma meeting milan criteria after curative resection.符合米兰标准的HBV相关肝细胞癌根治性切除术后早期复发的危险因素
Asian Pac J Cancer Prev. 2013;14(12):7101-6. doi: 10.7314/apjcp.2013.14.12.7101.
10
Clinical features of hepatocellular carcinoma developing extrahepatic recurrences after curative resection.肝细胞癌根治性切除术后发生肝外复发的临床特征。
World J Surg. 2008 Aug;32(8):1738-47. doi: 10.1007/s00268-008-9613-x.

引用本文的文献

1
Association Between Metabolic Health and Bone Mineral Density Using CT in Hepatocellular Carcinoma Patients Under 65: A Retrospective Chart Review.65岁以下肝细胞癌患者中代谢健康与使用CT测量的骨密度之间的关联:一项回顾性图表审查
Cureus. 2024 Oct 4;16(10):e70835. doi: 10.7759/cureus.70835. eCollection 2024 Oct.
2
Viral Status and Treatment Efficacy in Recurrent Hepatocellular Carcinoma After Primary Resection.原发性肝癌切除术后复发患者的病毒状态与治疗效果。
J Gastrointest Surg. 2023 Aug;27(8):1594-1610. doi: 10.1007/s11605-023-05691-z. Epub 2023 May 25.
3
Low adipocyte hepatocellular carcinoma is associated with aggressive cancer biology and with worse survival.低脂肪细胞型肝细胞癌与侵袭性癌症生物学行为及较差的生存率相关。
Am J Cancer Res. 2022 Aug 15;12(8):4028-4039. eCollection 2022.
4
Application of ultrasound combined with enhanced MRI by Gd-BOPTA in diagnosing hepatocellular carcinoma.钆布醇增强磁共振成像联合超声在肝细胞癌诊断中的应用
Am J Transl Res. 2021 Jun 15;13(6):7172-7178. eCollection 2021.

本文引用的文献

1
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
2
Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors.全球范围内主要危险因素所致肝细胞癌病例的发病率。
Eur J Cancer Prev. 2018 May;27(3):205-212. doi: 10.1097/CEJ.0000000000000428.
3
Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012.2000年至2012年美国50个州肝细胞癌的发病率
Gastroenterology. 2017 Mar;152(4):812-820.e5. doi: 10.1053/j.gastro.2016.11.020. Epub 2016 Nov 23.
4
Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands.肝硬化肝脏与非肝硬化肝脏中的肝细胞癌:来自荷兰一个大型队列的结果。
Eur J Gastroenterol Hepatol. 2016 Mar;28(3):352-9. doi: 10.1097/MEG.0000000000000527.
5
Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways.非肝硬化非酒精性脂肪性肝病中肝癌发生的发病机制:潜在的机制途径。
World J Hepatol. 2015 Oct 8;7(22):2384-8. doi: 10.4254/wjh.v7.i22.2384.
6
Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.美国退伍军人中无肝硬化的肝细胞癌与非酒精性脂肪性肝病相关。
Clin Gastroenterol Hepatol. 2016 Jan;14(1):124-31.e1. doi: 10.1016/j.cgh.2015.07.019. Epub 2015 Jul 18.
7
Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis.乙型肝炎病毒诱导肝癌发生的分子机制。
World J Gastroenterol. 2014 Sep 7;20(33):11630-40. doi: 10.3748/wjg.v20.i33.11630.
8
Emerging trends in hepatocellular carcinoma incidence and mortality.肝细胞癌发病率和死亡率的新趋势。
Hepatology. 2015 Jan;61(1):191-9. doi: 10.1002/hep.27388. Epub 2014 Nov 24.
9
Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver.非肝硬化肝脏中肝细胞癌(HCC)患者的特征及预后
BMC Gastroenterol. 2014 Jul 3;14:117. doi: 10.1186/1471-230X-14-117.
10
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.HBV 和 HCV 相关肝细胞癌的发病机制。
Nat Rev Cancer. 2013 Feb;13(2):123-35. doi: 10.1038/nrc3449.

无明确危险因素的肝细胞癌。

Hepatocellular carcinoma in patients with no identifiable risk factors.

机构信息

Department of Surgery, Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

HPB (Oxford). 2021 Jan;23(1):118-126. doi: 10.1016/j.hpb.2020.05.005. Epub 2020 Jun 24.

DOI:10.1016/j.hpb.2020.05.005
PMID:32591247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8022289/
Abstract

BACKGROUND

A subset of patients have no risk factors for the development of hepatocellular carcinoma (HCC). We evaluated differences in clinical variables between patients with and without risk factors who underwent surgical resection.

METHODS

A prospectively maintained database was queried for patients who underwent R0/R1 resection of HCC between 1992 and 2016. Risk factors included HCV, HBV, hemochromatosis, alcoholic liver disease, or cirrhosis, stage 2 or 3 fibrosis or severe (>66%) steatosis of the non-neoplastic liver. Variables were compared between patients with and without risk factors.

RESULTS

There were 416 patients who underwent resection; 276 (66%) had known risk factors while 140 (34%) did not. Patients without risk factors were more likely to be older, female and have hyperlipidemia or coronary artery disease (p < 0.004). These patients had larger tumors and were more likely to undergo major hepatectomy (p < 0.001). There was no difference in OS (5-year, 56% vs 47%, p = 0.335), RFS (27% vs 24%, p = 0.398), or the rates of intrahepatic (HR:1.16 [95%CI:0.95-1.57], p = 0.344) and extrahepatic recurrences (HR:0.72 [95%CI:0.4-1.3], p = 0.261) between groups.

CONCLUSION

Patients without risk factors for HCC presented with larger tumors yet had similar outcomes, suggesting these tumors may represent a different disease process, and underlying liver dysfunction can influence overall outcome.

摘要

背景

一部分患者没有发生肝细胞癌(HCC)的危险因素。我们评估了行根治性切除术的患者中有无危险因素者的临床变量差异。

方法

检索 1992 年至 2016 年间行 HCC 根治性切除术患者的前瞻性数据库。危险因素包括 HCV、HBV、血色病、酒精性肝病或肝硬化、2 或 3 期纤维化或非肿瘤性肝脏重度(>66%)脂肪变性。比较有危险因素和无危险因素患者的变量。

结果

共有 416 例患者行切除术;276 例(66%)有已知危险因素,140 例(34%)无危险因素。无危险因素的患者年龄更大,女性更多,血脂异常或冠心病更常见(p<0.004)。这些患者的肿瘤更大,更有可能接受大范围肝切除术(p<0.001)。OS(5 年,56%vs47%,p=0.335)、RFS(27%vs24%,p=0.398)和肝内(HR:1.16[95%CI:0.95-1.57],p=0.344)及肝外复发率(HR:0.72[95%CI:0.4-1.3],p=0.261)无差异。

结论

无 HCC 危险因素的患者表现为更大的肿瘤,但结局相似,提示这些肿瘤可能代表不同的疾病过程,基础肝功能障碍可能影响整体结局。